Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Operations (2016 - 2026)

Lexaria Bioscience's Cash from Operations history spans 12 years, with the latest figure at 2163872.0 for Q1 2026.

  • Quarterly results put Cash from Operations at 2163872.0 for Q1 2026, down 44.46% from a year ago — trailing twelve months through Feb 2026 was 9374421.0 (down 27.0% YoY), and the annual figure for FY2025 was 10450387.0, down 110.74%.
  • Cash from Operations for Q1 2026 was 2163872.0 at Lexaria Bioscience, down from 984098.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 619614.0 in Q1 2024 to a low of 3583953.0 in Q2 2025.
  • The 5-year median for Cash from Operations is 1277270.0 (2022), against an average of 1655977.18.
  • Peak annual rise in Cash from Operations hit 63.9% in 2025, while the deepest fall reached 183.08% in 2025.
  • Year by year, Cash from Operations stood at 1245313.0 in 2022, then increased by 5.11% to 1181653.0 in 2023, then plummeted by 130.7% to 2726045.0 in 2024, then skyrocketed by 63.9% to 984098.0 in 2025, then crashed by 119.88% to 2163872.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 2163872.0, 984098.0, and 2642498.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.